Some studies also showed that the GSDME promoter was also methylated in primary breast cancer cells (Kim et al., 2008b; Croes et al., 2017) and its expression may be up-regulated by treatment of epigenetic drugs, and treatment with DNA methyl-transferase inhibitor decitabine restored GSDME/DFNA5 expression in gastric cancer cell lines (Rogers et al., 2017; Lu et al., 2018), indicating combination with conventional chemotherapy drugs is more effective than each alone, but GSDME expression is a prerequisite. This evidence concerns the gene GSDME and breast carcinoma.